Table 2. . Phase III combination trials for the treatment of metastatic melanoma. Targeted therapy: BRAF^V600 inhibitors and MEK inhibitors combination.

Study	Treatment	Number of patients	Response rates (%)	Duration (months)	mPFS (months)	OS	>Grade 3 AEs (%)
COMBI-d	Dabrafenib + trametinib	211	69	12.9	11.0	25.1 months	32
	Dabrafenib + placebo	212	53	10.6	8.8	18.7 months	32
COMBI-v	Dabrafenib + trametinib	352	64	13.8	11.4	–	52
	Vemurafenib	352	51	7.5	7.3	–	63
Co-BRIM	Vemurafenib + cobimetinib	247	68	ND	9.9	81%†	65
	Vemurafenib + placebo	248	45	7.3	6.2	73%†	59

^†Overall survival rate at 9 months.

AE: Adverse event; mPFS: Median progresson-free survival; ND: Not determined; OS: Overall survival.

Data taken from [2,30–33].